Comparative Pharmacology
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus VALCHLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus VALCHLOR.
MELPHALAN HYDROCHLORIDE vs VALCHLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
Valchlor (mechlorethamine) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, leading to inhibition of DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
Topical: Apply 0.016% mechlorethamine gel to affected areas once daily.
None Documented
None Documented
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
The terminal elimination half-life is approximately 24 hours after topical application, supporting daily dosing. Systemic half-life may be prolonged in patients with hepatic impairment.
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Following topical application, VALCHLOR (mechlorethamine) is systemically absorbed; approximately <10% is excreted unchanged in urine. The majority of the dose is eliminated via metabolism and biliary/fecal routes, with ~50% of a systemic dose recovered in feces as metabolites.
Category D/X
Category C
Alkylating Agent
Alkylating Agent